Dear All: We need to make Pull incentives work! On this theme, our first topic for today is an opportunity for organizations to sign a letter of support for PASTEUR. This letter is co-led by the AMR Action Fund, BIO, Cystic Fibrosis Foundation, Infectious Diseases Society of America and Partnership to Fight Infectious Diseases. Here
Dear All: CARB-X have just announced their 2nd 2026 call for applications. There are 4 thematic areas for your proposals: Direct-acting therapeutics for infections caused by Gram-negative bacteria “Proposals must target the development of agents for the treatment of Gram-negative priority pathogens” (see our Bugs & Drugs page). Novel Chemistry for AMR Challenge: target-based therapeutics
Dear All: Significantly strengthening our database documenting the human cost of AMR, we now have an impressive survey of mortality associated with severe infections in 19 Asian countries during the period Sep 2022 to Feb 2025. Here are the links you need: (the primary paper): Mo Y, Hao X, Ding Y et al. Severe health-care-associated
Note: I’ve been away on holiday (see the newsletter’s postscript) and so there are multiple new items in both the meetings calendar and the list of funding opportunities: TB! PACCARB! Funding for antifungals! Funding for R&D in India! Look closely! Dear All: The AMR Multi-Stakeholder Partnership Platform (AMR MSPP) collaborated with the Milken Institute on
Dear All: An important and instructive analysis of optimal global antibiotic usage targets has just been published in Lancet Public Health. To follow the plot, here are the links you need: The new paper: Cook et al.: “Benchmarking AWaRe: estimating optimal levels of AWaRe antibiotic use in 186 countries, territories and areas based on clinical
Dear All: WHO have announced a very interesting 2-h virtual dialogue on optimal evidence generation across the antibiotic R&D lifecycle! Here are the details you need: When: 31 Aug 2026 (virtual, 2-4p CET): What: A dialogue on challenges such as fragmented regulatory requirements, trade-offs in clinical trial design, and gaps between evidence generated for regulatory
Dear All: Both FDA and EMA have very recently released important documents for comment. See below the links and commentary on the two documents. == FDA: The Substantial Evidence guidance, further updated: Comments due 22 Sep 2026 ==FDA have released a further revision of their Dec 2019 draft guidance entitled “Demonstrating Substantial Evidence of Effectiveness
Dear All: Two important webinars have just been announced! 22 July (virtual, 2-3.30p CET): The WHO AMR Department and the WHO GAP-r (Global Accelerator for Pediatric Formulations) are hosting an industry dialogue on pediatric and neonatal antibiotic development: The discussion will cover timing of pediatric and neonatal studies, extrapolation from adult data, feasibility of trial
Dear All: CDC have recently posted this eclectic mixture of funding opportunities that circle the globe! Funding opportunity: CDC-RFA-CK-26-0107 Title: “Building National Partnerships for the Prevention of Emerging and Reemerging Infectious Diseases“ Brief description: Seeks to build capacity in the United States to prevent, detect, and respond to infectious disease threats by building and sustaining
Dear All: Without much fanfare, we have an announcement that PACCARB (the US Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria) is being revived at a 16 June 2026 virtual meeting! Here are the links you need: 19 May 2026 Federal Register notice DHHS webpage about the meeting Date and time: 16 June 2026, 12.30-3.30p ET